Biohaven company information, Employees & Contact Information

Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire

Document SEC.gov

Biohaven Announces Up To $500 Million Non-Dilutive Term Loan With Sixth Street Sixth Street

Biohaven Names CEO Vlad Coric, MD, Chairman Of The Board Of Directors And Matthew Buten, Chief Financial Officer PR Newswire

Biohaven Pharmaceuticals to Host Inaugural Research & Development Day on November 26, 2018 PR Newswire

Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder PR Newswire

Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States PR Newswire

Biohaven Broadens Senior Leadership Team With Veteran Pharma Executives PR Newswire

Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled PR Newswire

Biohaven Provides Update On ESG Practices PR Newswire

Biohaven Enters Into Partnership With Medison Pharma To Distribute NURTEC™ ODT In Israel PR Newswire

Biohaven Provides Update On Phase 3 Trial And Multiple System Atrophy (MSA) Program PR Newswire

Biohaven Enrolls First Patient in Phase 2 Clinical Trial of Rimegepant, Oral CGRP Receptor Antagonist, for Treatment Refractory Trigeminal Neuralgia PR Newswire

Biohaven Completes Enrollment Ahead of Timelines in International Phase 3 Clinical Trial of Verdiperstat in Multiple System Atrophy PR Newswire

Biohaven Licenses Rights From Rutgers University To Develop And Commercialize Glutamate Modulating Agents In Cancer Treatment PR Newswire

Biohaven's Nurtec® ODT Signs as Official Migraine Partner of Big Machine Music City Grand Prix Race PR Newswire

Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy PR Newswire

Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy PR Newswire

Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences PR Newswire

Biohaven CEO Vlad Coric Named Ernst & Young Entrepreneur Of The Year 2018 Award Winner in New York Region PR Newswire

Biohaven's Oral Zavegepant, A Third Generation CGRP Receptor Antagonist, Receives Authorization To Proceed From FDA And Achieves First In Human Dosing PR Newswire

Biohaven Announces Patient Savings Program Where Patients Can Pay as Little as $0 for NURTEC™ ODT (rimegepant 75 mg) for the Acute Treatment of Migraine in Adults PR Newswire

Biohaven Signs Cody Ware as Driver for Nurtec® ODT Chevrolet for the 2021 NASCAR Cup Series Season PR Newswire

Biohaven Announces Issuance of Composition of Matter Patent on Troriluzole by the U.S. Patent and Trademark Office PR Newswire

NURTEC® ODT Approved In Kuwait For Acute Treatment Of Migraine PR Newswire

Biohaven's Troriluzole Successfully Advances Past Interim Futility Analysis In Pivotal Phase 2/3 Alzheimer's Disease Study PR Newswire

Biohaven's NURTEC® ODT Approved In Israel For Acute Treatment Of Migraine PR Newswire

Biohaven Enrolls First Patient In Phase 3 Spinocerebellar Ataxia Clinical Trial Of Troriluzole PR Newswire

Biohaven Licenses Novel Myeloperoxidase Inhibitor From AstraZeneca: Potential First-In-Class Treatment For Multiple System Atrophy PR Newswire

Biohaven's NURTEC™ ODT (rimegepant 75mg) is Now Available in U.S. Pharmacies for the Acute Treatment of Migraine in Adults PR Newswire

Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint PR Newswire

Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy , from Bristol Myers Squibb Investing News Network

Troriluzole No Better Than Placebo in Generalized Anxiety Disorder Study Medical Professionals Reference